Literature DB >> 26432089

[Resistant fungi].

M J G T Vehreschild1,2, O A Cornely3,4,5.   

Abstract

Particularly in the area of hematology/oncology and intensive care medicine, infections due to resistant fungi are to be expected. Emergence of resistance in fungi is a less dynamic process than in bacteria; it can, however, have an equally important impact on treatment strategies. In the following article, the most important resistance patterns of yeasts and molds (Candida albicans , Aspergillus fumigatus, the order Mucorales and the genus Fusarium) will be presented and discussed. Their diagnosis mostly being based on blood cultures, resistance testing for yeasts is usually readily available. Culture-based therapeutic adjustments in mold infections are, however, only rarely possible, as most antifungal therapies for these infections are initiated on an empirical basis after identification of typical infiltrates on a CT scan. Response to therapy is then evaluated on the basis of clinical signs and symptoms in combination with follow-up CT scans. In case of therapeutic failure or appearance of suspicious infiltrates under antifungal prophylaxis, an open or CT-guided biopsy is recommended to allow efficient adaptation of antifungal treatment. In individual cases, particularly in patients diagnosed with mucormycosis, resection of the focus of infection may be necessary to achieve a satisfactory treatment response.

Entities:  

Keywords:  Antifungal agents; Azole resistance; Fungal infections, rare; Molds; Yeasts

Mesh:

Substances:

Year:  2015        PMID: 26432089     DOI: 10.1007/s00108-015-3704-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  24 in total

1.  Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis.

Authors:  Andrea G Varon; Simone A Nouer; Gloria Barreiros; Beatriz Moritz Trope; Fabiana Magalhães; Tiyomi Akiti; Marcia Garnica; Marcio Nucci
Journal:  J Infect       Date:  2013-08-28       Impact factor: 6.072

2.  Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany.

Authors:  J Steinmann; A Hamprecht; M J G T Vehreschild; O A Cornely; D Buchheidt; B Spiess; M Koldehoff; J Buer; J F Meis; P-M Rath
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

3.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

4.  Improvement in the outcome of invasive fusariosis in the last decade.

Authors:  M Nucci; K A Marr; M J G T Vehreschild; C A de Souza; E Velasco; P Cappellano; F Carlesse; F Queiroz-Telles; D C Sheppard; A Kindo; S Cesaro; N Hamerschlak; C Solza; W J Heinz; M Schaller; A Atalla; S Arikan-Akdagli; H Bertz; C Galvão Castro; R Herbrecht; M Hoenigl; G Härter; N E U Hermansen; A Josting; L Pagano; M J C Salles; S B Mossad; D Ogunc; A C Pasqualotto; V Araujo; P F Troke; O Lortholary; O A Cornely; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2013-11-18       Impact factor: 8.067

5.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Authors:  William J Steinbach; Kieren A Marr; Elias J Anaissie; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; Senu Apewokin; David L Horn
Journal:  J Infect       Date:  2012-08-13       Impact factor: 6.072

6.  Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients.

Authors:  Birgit Spiess; Wolfgang Seifarth; Natalia Merker; Susan J Howard; Mark Reinwald; Anne Dietz; Wolf-Karsten Hofmann; Dieter Buchheidt
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

7.  A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates.

Authors:  G Blum; S Perkhofer; K Grif; A Mayr; G Kropshofer; D Nachbaur; R Kafka-Ritsch; M P Dierich; C Lass-Flörl
Journal:  Clin Microbiol Infect       Date:  2008-12       Impact factor: 8.067

8.  Environmental fungicides and triazole resistance in Aspergillus.

Authors:  Paul Bowyer; David W Denning
Journal:  Pest Manag Sci       Date:  2013-12-05       Impact factor: 4.845

9.  Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity.

Authors:  Cornelia Lass-Flörl; Katharina Grif; Dimitrios P Kontoyiannis
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

Review 10.  Our 2014 approach to mucormycosis.

Authors:  Daniela Tacke; Philipp Koehler; Birgid Markiefka; Oliver A Cornely
Journal:  Mycoses       Date:  2014-05-15       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.